Omega-3 fatty acids protect renal functions by increasing docosahexaenoic acid-derived metabolite levels in SHR.cg-leprcp/NDmcr rats, a metabolic syndrome model

Masanori Katakura, Michio Hashimoto, Takayuki Inoue, Abdullah Al Mamun, Yoko Tanabe, Ryo Iwamoto, Makoto Arita, Satoru Tsuchikura, Osamu Shido

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The omega-3 polyunsaturated fatty acids (?-3 PUFAs) docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA) protect against diabetic nephropathy by inhibiting inflammation. The aim of this study was to assess the effects of highly purified DHA and EPA or EPA only administration on renal function and renal eicosanoid and docosanoid levels in an animal model of metabolic syndrome, SHR.Cg-Leprcp/NDmcr (SHRcp) rats. Male SHRcp rats were divided into 3 groups. Control (5% arabic gum), TAK-085 (300 mg/kg/day, containing 467 mg/g EPA and 365 mg/g DHA), or EPA (300 mg/kg/day) was orally administered for 20 weeks. The urinary albumin to creatinine ratio in the TAK-085-administered group was significantly lower than that in other groups. The glomerular sclerosis score in the TAK-085-administered group was significantly lower than that in the other groups. Although DHA levels were increased in total kidney fatty acids, the levels of nonesterified DHA were not significantly different among the 3 groups, whereas the levels of protectin D1, resolvin D1, and resolvin D2 were significantly increased in the TAK-085-administered group. The results show that the use of combination therapy with DHA and EPA in SHRcp rats improved or prevented renal failure associate with metabolic syndrome with decreasing triglyceride levels and increasing ?-3 PUFA lipid mediators.

Original languageEnglish
Pages (from-to)3247-3263
Number of pages17
JournalMolecules
Volume19
Issue number3
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

renal function
Eicosapentaenoic Acid
Docosahexaenoic Acids
metabolites
Omega-3 Fatty Acids
fatty acids
Metabolites
rats
Rats
Kidney
acids
Gum Arabic
Eicosanoids
Diabetic Nephropathies
Sclerosis
Unsaturated Fatty Acids
Nonesterified Fatty Acids
Renal Insufficiency
Albumins
Creatinine

Keywords

  • Diabetic nephropathy
  • Lipidomics
  • Protectin
  • Resolvin

ASJC Scopus subject areas

  • Organic Chemistry
  • Medicine(all)

Cite this

Omega-3 fatty acids protect renal functions by increasing docosahexaenoic acid-derived metabolite levels in SHR.cg-leprcp/NDmcr rats, a metabolic syndrome model. / Katakura, Masanori; Hashimoto, Michio; Inoue, Takayuki; Mamun, Abdullah Al; Tanabe, Yoko; Iwamoto, Ryo; Arita, Makoto; Tsuchikura, Satoru; Shido, Osamu.

In: Molecules, Vol. 19, No. 3, 2014, p. 3247-3263.

Research output: Contribution to journalArticle

Katakura, Masanori ; Hashimoto, Michio ; Inoue, Takayuki ; Mamun, Abdullah Al ; Tanabe, Yoko ; Iwamoto, Ryo ; Arita, Makoto ; Tsuchikura, Satoru ; Shido, Osamu. / Omega-3 fatty acids protect renal functions by increasing docosahexaenoic acid-derived metabolite levels in SHR.cg-leprcp/NDmcr rats, a metabolic syndrome model. In: Molecules. 2014 ; Vol. 19, No. 3. pp. 3247-3263.
@article{91768d696e9246c98404427797c02ff2,
title = "Omega-3 fatty acids protect renal functions by increasing docosahexaenoic acid-derived metabolite levels in SHR.cg-leprcp/NDmcr rats, a metabolic syndrome model",
abstract = "The omega-3 polyunsaturated fatty acids (?-3 PUFAs) docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA) protect against diabetic nephropathy by inhibiting inflammation. The aim of this study was to assess the effects of highly purified DHA and EPA or EPA only administration on renal function and renal eicosanoid and docosanoid levels in an animal model of metabolic syndrome, SHR.Cg-Leprcp/NDmcr (SHRcp) rats. Male SHRcp rats were divided into 3 groups. Control (5{\%} arabic gum), TAK-085 (300 mg/kg/day, containing 467 mg/g EPA and 365 mg/g DHA), or EPA (300 mg/kg/day) was orally administered for 20 weeks. The urinary albumin to creatinine ratio in the TAK-085-administered group was significantly lower than that in other groups. The glomerular sclerosis score in the TAK-085-administered group was significantly lower than that in the other groups. Although DHA levels were increased in total kidney fatty acids, the levels of nonesterified DHA were not significantly different among the 3 groups, whereas the levels of protectin D1, resolvin D1, and resolvin D2 were significantly increased in the TAK-085-administered group. The results show that the use of combination therapy with DHA and EPA in SHRcp rats improved or prevented renal failure associate with metabolic syndrome with decreasing triglyceride levels and increasing ?-3 PUFA lipid mediators.",
keywords = "Diabetic nephropathy, Lipidomics, Protectin, Resolvin",
author = "Masanori Katakura and Michio Hashimoto and Takayuki Inoue and Mamun, {Abdullah Al} and Yoko Tanabe and Ryo Iwamoto and Makoto Arita and Satoru Tsuchikura and Osamu Shido",
year = "2014",
doi = "10.3390/molecules19033247",
language = "English",
volume = "19",
pages = "3247--3263",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - Omega-3 fatty acids protect renal functions by increasing docosahexaenoic acid-derived metabolite levels in SHR.cg-leprcp/NDmcr rats, a metabolic syndrome model

AU - Katakura, Masanori

AU - Hashimoto, Michio

AU - Inoue, Takayuki

AU - Mamun, Abdullah Al

AU - Tanabe, Yoko

AU - Iwamoto, Ryo

AU - Arita, Makoto

AU - Tsuchikura, Satoru

AU - Shido, Osamu

PY - 2014

Y1 - 2014

N2 - The omega-3 polyunsaturated fatty acids (?-3 PUFAs) docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA) protect against diabetic nephropathy by inhibiting inflammation. The aim of this study was to assess the effects of highly purified DHA and EPA or EPA only administration on renal function and renal eicosanoid and docosanoid levels in an animal model of metabolic syndrome, SHR.Cg-Leprcp/NDmcr (SHRcp) rats. Male SHRcp rats were divided into 3 groups. Control (5% arabic gum), TAK-085 (300 mg/kg/day, containing 467 mg/g EPA and 365 mg/g DHA), or EPA (300 mg/kg/day) was orally administered for 20 weeks. The urinary albumin to creatinine ratio in the TAK-085-administered group was significantly lower than that in other groups. The glomerular sclerosis score in the TAK-085-administered group was significantly lower than that in the other groups. Although DHA levels were increased in total kidney fatty acids, the levels of nonesterified DHA were not significantly different among the 3 groups, whereas the levels of protectin D1, resolvin D1, and resolvin D2 were significantly increased in the TAK-085-administered group. The results show that the use of combination therapy with DHA and EPA in SHRcp rats improved or prevented renal failure associate with metabolic syndrome with decreasing triglyceride levels and increasing ?-3 PUFA lipid mediators.

AB - The omega-3 polyunsaturated fatty acids (?-3 PUFAs) docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA) protect against diabetic nephropathy by inhibiting inflammation. The aim of this study was to assess the effects of highly purified DHA and EPA or EPA only administration on renal function and renal eicosanoid and docosanoid levels in an animal model of metabolic syndrome, SHR.Cg-Leprcp/NDmcr (SHRcp) rats. Male SHRcp rats were divided into 3 groups. Control (5% arabic gum), TAK-085 (300 mg/kg/day, containing 467 mg/g EPA and 365 mg/g DHA), or EPA (300 mg/kg/day) was orally administered for 20 weeks. The urinary albumin to creatinine ratio in the TAK-085-administered group was significantly lower than that in other groups. The glomerular sclerosis score in the TAK-085-administered group was significantly lower than that in the other groups. Although DHA levels were increased in total kidney fatty acids, the levels of nonesterified DHA were not significantly different among the 3 groups, whereas the levels of protectin D1, resolvin D1, and resolvin D2 were significantly increased in the TAK-085-administered group. The results show that the use of combination therapy with DHA and EPA in SHRcp rats improved or prevented renal failure associate with metabolic syndrome with decreasing triglyceride levels and increasing ?-3 PUFA lipid mediators.

KW - Diabetic nephropathy

KW - Lipidomics

KW - Protectin

KW - Resolvin

UR - http://www.scopus.com/inward/record.url?scp=84896909151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896909151&partnerID=8YFLogxK

U2 - 10.3390/molecules19033247

DO - 10.3390/molecules19033247

M3 - Article

C2 - 24642910

AN - SCOPUS:84896909151

VL - 19

SP - 3247

EP - 3263

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 3

ER -